Danaher에 대한 매도 수량은 투자자에게 Danaher의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Danaher (NYSE:DHR) 주식, 공매도 수량 보고

Danaher

In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divesititure of its environmental and applied solutions group, Veralto.

Analyst Color

Earnings

Equities

News

Guidance

Health Care

Price Target

Reiteration

Analyst Ratings

Trading Ideas

General

화요일에, 다나허(NYSE:DHR)는 3분기 매출이 57억 9천만 달러로 전년 대비 3% 증가했으며, 컨센서스 55억 9천만 달러를 상회했다고 보고했다. 가이던스: 다나허(Danaher)는 2024 회계연도 비GAAP 핵심 매출이 전년 대비 낮은 한 자릿수로 감소할 것임을 재확인했다.

다나허의 3분기 실적은 바이오프로세싱 주문 증가로 인해 증가, 분석가는 주식 등급 유지

Movers

AVTR

CBRE

ENPH

FCNCA

LPLA

MANH

SIRI

SPOT

이들 11개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? QXO(NASDAQ:QXO)의 주가는 사모 금융 유치를 발표한 이후 33.37% 상승했다.

유니버셜 헬스 및 록히드 마틴은 지난주 최고 성과를 보여준 11개 대형주 중 일부 (7월 21일-7월 27일)

Danaher Corp

DEUTSCHE EUROSHOP UNS/ADR by Deutsche Euroshop AG

Deutsche EuroShop AG

WIIM

Danaher shares are trading lower after Third Point in a 13F disclosed that it decreased its stake in the company by 5%

AAPL

AMZN

MSFT

Third Point 13F Shows Decreased Stake In PG&E Corp By 7% From 53,750,000 To 49,750,000 Shares; Amazon By 27% From 5,100,000 To 3,700,000 Shares; Danaher Corp By 5% From 2,050,000 To 1,950,000 Shares; Vistra Corp By 29% From 4,470,000 To 3,175,000 Shares; Microsoft By 45% From 1,580,000 To 870,000 Shares; Meta Platforms By 50% From 1,100,000  To 545,000 Shares; TSM By 12% From 2,025,000 To 1,780,000 Shares; Apple By 52% From 1,950,000 To 930,000 Shares; Amphenol Corp By 43% From 2,800,000 To 1,600,000 Shares

Danaher's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) short percent of float has fallen 5.68% since its last report. The company recently reported that it has 5.32 million shares sold short, which is 0.83% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.63 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Danaher Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730733432_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Danaher has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Danaher's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Danaher's peer group average for short interest as a percentage of float is 5.39%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Danaher's Recent Short Interest

In the fast-paced and highly competitive business world of today, conducting thorough company analysis is essential for investors and industry observers. In this article, we will conduct an extensive industry comparison, evaluating Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) in relation to its major competitors in the Life Sciences Tools &amp; Services industry. Through a detailed examination of key financial metrics, market standing, and growth prospects, our objective is to provide valuable insights and illuminate company's performance in the industry.
<h3>Danaher Background</h3>
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divesititure of its environmental and applied solutions group, Veralto.
<table>
<thead>
<tr>
<th>Company</th>
<th>P/E</th>
<th>P/B</th>
<th>P/S</th>
<th>ROE</th>
<th>EBITDA (in billions)</th>
<th>Gross Profit (in billions)</th>
<th>Revenue Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Danaher Corp</td>
<td>46.75</td>
<td>3.49</td>
<td>7.74</td>
<td>1.62%</td>
<td>$1.66</td>
<td>$3.4</td>
<td>3.09%</td>
</tr>
<tr>
<td>Thermo Fisher Scientific Inc</td>
<td>34.98</td>
<td>4.36</td>
<td>5.06</td>
<td>3.38%</td>
<td>$2.91</td>
<td>$4.35</td>
<td>0.54%</td>
</tr>
<tr>
<td>Agilent Technologies Inc</td>
<td>28.46</td>
<td>6.66</td>
<td>6.19</td>
<td>4.65%</td>
<td>$0.43</td>
<td>$0.85</td>
<td>-5.62%</td>
</tr>
<tr>
<td>IQVIA Holdings Inc</td>
<td>27.48</td>
<td>5.45</td>
<td>2.52</td>
<td>4.17%</td>
<td>$0.8</td>
<td>$1.38</td>
<td>4.28%</td>
</tr>
<tr>
<td>Waters Corp</td>
<td>36.95</td>
<td>14.34</td>
<td>7.92</td>
<td>10.71%</td>
<td>$0.24</td>
<td>$0.42</td>
<td>4.02%</td>
</tr>
<tr>
<td>West Pharmaceutical Services Inc</td>
<td>46.96</td>
<td>8.33</td>
<td>8.15</td>
<td>5.1%</td>
<td>$0.21</td>
<td>$0.26</td>
<td>-0.07%</td>
</tr>
<tr>
<td>Avantor Inc</td>
<td>49.58</td>
<td>2.73</td>
<td>2.23</td>
<td>1.05%</td>
<td>$0.23</td>
<td>$0.56</td>
<td>-0.34%</td>
</tr>
<tr>
<td>Revvity Inc</td>
<td>75.65</td>
<td>1.90</td>
<td>5.52</td>
<td>0.7%</td>
<td>$0.22</td>
<td>$0.39</td>
<td>-2.45%</td>
</tr>
<tr>
<td>Bio-Techne Corp</td>
<td>79.27</td>
<td>5.59</td>
<td>10.32</td>
<td>1.6%</td>
<td>$0.07</td>
<td>$0.2</td>
<td>-5.44%</td>
</tr>
<tr>
<td>Medpace Holdings Inc</td>
<td>27.98</td>
<td>11.27</td>
<td>4.94</td>
<td>11.72%</td>
<td>$0.12</td>
<td>$0.17</td>
<td>8.29%</td>
</tr>
<tr>
<td>Charles River Laboratories International Inc</td>
<td>21.65</td>
<td>2.51</td>
<td>2.29</td>
<td>2.44%</td>
<td>$0.24</td>
<td>$0.35</td>
<td>-3.19%</td>
</tr>
<tr>
<td>Bruker Corp</td>
<td>24.81</td>
<td>5.02</td>
<td>2.79</td>
<td>0.47%</td>
<td>$0.08</td>
<td>$0.38</td>
<td>17.42%</td>
</tr>
<tr>
<td>Stevanato Group SpA</td>
<td>39.22</td>
<td>4.39</td>
<td>4.43</td>
<td>1.55%</td>
<td>$0.05</td>
<td>$0.07</td>
<td>1.67%</td>
</tr>
<tr>
<td>Sotera Health Co</td>
<td>113.29</td>
<td>10.62</td>
<td>4.10</td>
<td>2.05%</td>
<td>$0.1</td>
<td>$0.15</td>
<td>8.35%</td>
</tr>
<tr>
<td>Average</td>
<td>46.64</td>
<td>6.4</td>
<td>5.11</td>
<td>3.81%</td>
<td>$0.44</td>
<td>$0.73</td>
<td>2.11%</td>
</tr>
</tbody>
</table>
<style>
 table {
 width: 100%;
 border-collapse: collapse;
 font-family: Arial, sans-serif;
 font-size: 14px;
 }

 th, td {
 padding: 8px;
 text-align: left;
 }

 th {
 background-color: #293a5a;
 color: #fff;
 text-align: left;
 }

 tr:nth-child(even) {
 background-color: #f2f4f8;
 }

 tr:hover {
 background-color: #e1e4ea;
 }

 td:nth-child(3), td:nth-child(5) {
 text-align: left;
 }

 .dividend-amount {
 font-weight: bold;
 color: #0d6efd;
 }

 .dividend-frequency {
 font-size: 12px;
 color: #6c757d;
 }
 </style>Upon a comprehensive analysis of Danaher, the following trends can be discerned: 
<ul>
<li>
The Price to Earnings ratio of 46.75 for this company is 1.0x above the industry average, indicating a premium valuation associated with the stock.
</li>
<li>
With a Price to Book ratio of 3.49, significantly falling below the industry average by 0.55x, it suggests undervaluation and the possibility of untapped growth prospects.
</li>
<li>
The stock's relatively high Price to Sales ratio of 7.74, surpassing the industry average by 1.51x, may indicate an aspect of overvaluation in terms of sales performance.
</li>
<li>
The company has a lower Return on Equity (ROE) of 1.62%, which is 2.19% below the industry average. This indicates potential inefficiency in utilizing equity to generate profits, which could be attributed to various factors.
</li>
<li>
With higher Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $1.66 Billion, which is 3.77x above the industry average, the company demonstrates stronger profitability and robust cash flow generation.
</li>
<li>
Compared to its industry, the company has higher gross profit of $3.4 Billion, which indicates 4.66x above the industry average, indicating stronger profitability and higher earnings from its core operations.
</li>
<li>
The company is experiencing remarkable revenue growth, with a rate of 3.09%, outperforming the industry average of 2.11%.
</li>
</ul>
<h3>Debt To Equity Ratio</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730732622_0.png" alt="debt to equity" />
The debt-to-equity (D/E) ratio indicates the proportion of debt and equity used by a company to finance its assets and operations.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
When assessing Danaher against its top 4 peers using the Debt-to-Equity ratio, the following comparisons can be made:
<ul>
<li>
Danaher exhibits a stronger financial position compared to its top 4 peers in the sector, as indicated by its lower debt-to-equity ratio of 0.34.
</li>
<li>
This suggests that the company has a more favorable balance between debt and equity, which can be seen as a positive aspect for investors.
</li>
</ul>
<h3>Key Takeaways</h3>
For Danaher in the Life Sciences Tools &amp; Services industry, the PE ratio is high compared to peers, indicating potential overvaluation. The PB ratio is low, suggesting a possible undervaluation relative to industry standards. The PS ratio is high, signaling a premium valuation based on sales. In terms of ROE, Danaher shows lower profitability compared to peers. However, its high EBITDA, gross profit, and revenue growth reflect strong operational performance within the industry sector.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Markets

Inquiry Into Danaher's Competitor Dynamics In Life Sciences Tools &amp; Services Industry

In the current market session, Danaher Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) share price is at $242.91, after a 0.09% spike. Moreover, over the past month, the stock decreased by 8.25%, but in the past year, went up by 26.72%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2024/1730491548_0.png" alt="Past Year Chart" />

<h3>Danaher P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Danaher has a better P/E ratio of 45.79 than the aggregate P/E ratio of 43.15 of the Life Sciences Tools &amp; Services industry. Ideally, one might believe that Danaher Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1730491548_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

A Look Into Danaher Inc's Price Over Earnings

Wolfe Research analyst Doug Schenkel upgrades Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) from Peer Perform to Outperform and announces $285 price target.

Upgrades

Wolfe Research Upgrades Danaher to Outperform, Announces $285 Price Target

Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) has outperformed the market over the past 10 years by 5.16% on an annualized basis producing an average annual return of 16.37%. Currently, Danaher has a market capitalization of $176.82 billion. 
Buying $1000 In DHR: If an investor had bought $1000 of DHR stock 10 years ago, it would be worth $4,556.76 today based on a price of $244.81 for DHR at the time of writing.
<h3>Danaher's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730129417_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 10 Years Ago, You Would Have $4,600 Today

RBC Capital analyst Conor McNamara maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Outperform and lowers the price target from $333 to $311.

RBC Capital Maintains Outperform on Danaher, Lowers Price Target to $311

TD Cowen analyst Dan Brennan maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Buy and raises the price target from $310 to $315.

TD Cowen Maintains Buy on Danaher, Raises Price Target to $315

Stephens &amp; Co. analyst Jacob Johnson reiterates Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Overweight and maintains $315 price target.

Stephens & Co. Reiterates Overweight on Danaher, Maintains $315 Price Target

Stifel analyst Daniel Arias maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Hold and raises the price target from $250 to $265.

Stifel Maintains Hold on Danaher, Raises Price Target to $265

UBS analyst Dan Leonard maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Buy and lowers the price target from $309 to $305.

UBS Maintains Buy on Danaher, Lowers Price Target to $305

Raymond James analyst Andrew Cooper maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Outperform and lowers the price target from $310 to $300.

Raymond James Maintains Outperform on Danaher, Lowers Price Target to $300

Keybanc analyst Paul Knight maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Overweight and raises the price target from $290 to $310.

Keybanc Maintains Overweight on Danaher, Raises Price Target to $310

Barclays analyst Luke Sergott maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Equal-Weight and lowers the price target from $285 to $275.

Barclays Maintains Equal-Weight on Danaher, Lowers Price Target to $275

Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Danaher, presenting an average target of $290.0, a high estimate of $315.00, and a low estimate of $277.00. This current average has increased by 1.99% from the previous average price target of $284.33. 
<img src="https://www.benzinga.com/files/images/story/2024/1729684856_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Danaher by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Catherine Schulte</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$277.00</td>
<td>$278.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$278.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Jacob Johnson</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Overweight</td>
<td>$315.00</td>
<td>-</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$280.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Danaher. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Danaher compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Danaher's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Danaher's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DHR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Danaher analyst ratings.</a>
<h2>Unveiling the Story Behind Danaher</h2>
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divesititure of its environmental and applied solutions group, Veralto.
<h3>Danaher: A Financial Overview</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Negative Revenue Trend: Examining Danaher's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately -2.86% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Danaher's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 15.79% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Danaher's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.76% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Danaher's ROA excels beyond industry benchmarks, reaching 1.12%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.34.
<h2>What Are Analyst Ratings?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Critical Insights From Danaher Analyst Ratings: What You Need To Know

Baird analyst Catherine Schulte maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Outperform and lowers the price target from $278 to $277.

Baird Maintains Outperform on Danaher, Lowers Price Target to $277

On Tuesday,&nbsp;Danaher Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) reported third-quarter sales of $5.79 billion, up 3% year-over-year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41449367/life-science-giant-danaher-q3-earnings-revenue-and-eps-beat-sticks-to-annual-guidance" rel="noreferrer noopener">consensus of $5.59 billion</a>.&nbsp;
Guidance: Danaher reaffirms that in fiscal year 2024, non-GAAP core revenue will be down in the low single digits year over year.
The company forecasts that 2024 bioprocessing core revenue will decline in the low single digits, and Cepheid 2024 respiratory revenues will be around&nbsp;$1.7 billion compared to prior guidance of $1.6 billion.
William Blair reports that Danaher&#8217;s third-quarter earnings aligned with expectations, particularly regarding the ongoing recovery in bioprocessing, though capital expenditures remain weak.
The analyst highlights that the recovery theme is progressing as anticipated, with results reflecting similar trends seen in industry conference updates earlier in the quarter.
Third-quarter book-to-bill improved to approximately 1.0x, up from 0.80x a year ago, and a high-single-digit increase in sequential orders further supported the bioprocessing rebound.
In the equipment segment, life sciences instruments saw a mid-single-digit decline, in line with forecasts and intra-quarter observations.
Meanwhile, diagnostics performed well, and Cepheid&#8217;s respiratory revenue again exceeded expectations.
On guidance, management expects mid- to high-single-digit core growth in the fourth quarter in Biotechnology. The analyst expects the focus of the call will be on the fourth-quarter exit rate for bioprocessing, any initial insights into 2025, capital equipment weakness, and updated thoughts on China.
William Blair keeps the Outperform rating. Goldman Sachs maintains a Neutral rating,<a href="https://www.benzinga.com/quote/dhr/analyst-ratings"> with a price target of $250.</a>
Price Action: DHR stock is down 4.01% at $261.18 at last check Tuesday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41462205/with-fda-approval-irhythm-may-be-able-to-lift-regulatory-overhang-investor-skeptici" target="_blank" rel="noreferrer noopener">With FDA Approval iRhythm May Be Able To Lift Regulatory Overhang, Investor Skepticism, Analyst Says</a>.</li>
</ul>

Danaher's Q3 Earnings Boosted By Bioprocessing Order Growth, Analyst Maintain Stock Rating

Wall Street traded lower for the second consecutive day on Tuesday, as investor sentiment turned cautious with the U.S. presidential election <a href="https://www.benzinga.com/topic/2024-elections">just two weeks away. </a>
Concerns over U.S. fiscal policies and potential shifts in economic direction fueled the pause in risk-taking.
The International Monetary Fund (IMF) upgraded its U.S. growth forecasts for 2024 and 2025 in the latest World Economic Outlook, while also flagging rising concerns about the country's debt trajectory, warning that with current large fiscal deficits, &#8220;the U.S. public debt is not stabilized.&#8221;
Commodities were the standout performers on Tuesday, with both metals and energy experiencing notable gains.
Gold, tracked by the SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>), rose 0.8%, pushing further into record territory. This increase extended its year-to-date performance to 34%, positioning gold for its strongest <a href="https://www.benzinga.com/markets/bonds/24/10/41455678/gold-on-track-for-best-year-since-1979-veteran-investor-says-sell-bonds-buy-gold">annual gain since 1979.</a> Gold miners, as represented by the VanEck Gold Miners ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDX#NYSE">GDX</a>), rallied for the ninth consecutive session, hitting their highest levels in over four years.
Silver, tracked by the iShares Silver Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLV#NYSE">SLV</a>), surged 2.8%, reaching levels not seen since October 2012.
Oil prices rallied nearly 3%, building on a 2% surge from Monday. U.S. Treasury yields ticked up modestly on Tuesday following Monday's spike, with the 10-year yield settling at 4.21%.
Meanwhile, the U.S. Dollar Index (DXY), tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), climbed past the 104 mark, continuing its steady ascent and eyeing a fourth consecutive week of gains.
In the cryptocurrency market, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) fell 0.5%, dipping to around $67,000 and marking its second consecutive day of declines.
<h3 class="wp-block-heading">Tuesday&#8217;s Performance In US Major Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %change</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,907.57</td>
<td>-0.1 %</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,840.39</td>
<td>-0.2%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,291.15</td>
<td>-0.3%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,228.60</td>
<td>-0.5%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:35 p.m. ET</figcaption></figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent102224&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) fell 0.3% to $581.79.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;inched 0.1% lower to $429.14.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) fell 0.4% to $493.29.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) fell 0.5% $221.04.</li>
<li>The Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) outperformed, up 0.6%. The Industrial Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>) lagged, down 1.1%.</li>
</ul>
<h3 class="wp-block-heading">Tuesday&#8217;s Stock Performers</h3>
General Motors Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) surged 9%, on track for its strongest session in nearly a year, after reporting stronger-than-expected earnings and announcing an additional $5 billion share buyback program extending into next year.
Other stocks reacting to earnings include: 
<ul>
<li>Southern Copper Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCCO#NYSE">SCCO</a>), up 1.5%</li>
<li>Nucor Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>), down 6%</li>
<li>W.R. Berkley Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRB#NYSE">WRB</a>), down 4.6%</li>
<li>Zion Bancorp. N.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZION#NASDAQ">ZION</a>), up 6.8%</li>
<li>Wintrust Financial Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTFC#NASDAQ">WTFC</a>), up 1.6%</li>
<li>Philip Morris International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>), up 8.8%</li>
<li>GE Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>), down over 8%</li>
<li>Danaher Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), down 3%</li>
<li>Verizon Communications Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>), down 4.4%</li>
<li>RTX Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>), down 0.4%</li>
<li>Lockheed Martin Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>), down 5.8%</li>
<li>Fiserv Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>), down 0.4%</li>
<li>Moodys Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCO#NYSE">MCO</a>) down 4.5%</li>
<li>3M Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>), down 0.9%</li>
<li>Freeport-McMoran Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>), up 1.4%</li>
<li>Kimberly-Clark Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NYSE">KMB</a>), down 4%</li>
<li>PulteGroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHM#NYSE">PHM</a>), down 5.7%</li>
</ul>
Large-cap companies reporting earnings after the close include Texas Instruments Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>), Baker Hughes Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>), Seagate Technology Holdings PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>), Packaging Corporation of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKG#NYSE">PKG</a>), Manhattan Associates Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>), East West Bancorp. Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWBC#NASDAQ">EWBC</a>) and Enphase Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>)
Now Read:
<ul>
<li><a href="https://www.benzinga.com/government/24/10/41455013/how-us-elections-could-impact-us-dollar-goldman-sachs-expects-greenback-will-remain-stronger-for-lon">How US Elections Could Impact US Dollar: Goldman Sachs Expects Greenback Will Remain &#8216;Stronger For Longer&#8217;</a></li>
</ul>
Image: Shutterstock

Large Cap

Mid Cap

Sector ETFs

Broad U.S. Equity ETFs

New ETFs

Commodities

Currency ETFs

Small Cap

Tech

ETFs

$BTC

SPDR Dow Jones Industrial Average ETF Trust

EWBC

Market Vectors ETF Trust Market Vectors Gold Miners

SCCO

PowerShares DB US Dollar Index Bullish Fund

WTFC

ZION

Stocks Fall, GM Eyes Best Day In A Year, Gold Breaks Records, Silver Hits 12-Year Highs: What's Driving Markets Tuesday?

Deep-pocketed investors have adopted a bearish approach towards Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in DHR usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 18 extraordinary options activities for Danaher. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 33% leaning bullish and 44% bearish. Among these notable options, 13 are puts, totaling $1,262,580, and 5 are calls, amounting to $222,084.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $150.0 to $290.0 for Danaher over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Danaher stands at 425.44, with a total volume reaching 2,026.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Danaher, situated within the strike price corridor from $150.0 to $290.0, throughout the last 30 days.
<h3>Danaher Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729611930_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$25.4</td>
<td>$24.8</td>
<td>$25.4</td>
<td>$290.00</td>
<td>$151.8K</td>
<td>245</td>
<td style="text-align: right;">60</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$27.4</td>
<td>$24.3</td>
<td>$25.55</td>
<td>$290.00</td>
<td>$145.6K</td>
<td>245</td>
<td style="text-align: right;">117</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$19.3</td>
<td>$16.3</td>
<td>$17.75</td>
<td>$280.00</td>
<td>$106.5K</td>
<td>1.1K</td>
<td style="text-align: right;">275</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$19.3</td>
<td>$16.4</td>
<td>$18.43</td>
<td>$280.00</td>
<td>$105.0K</td>
<td>1.1K</td>
<td style="text-align: right;">332</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$16.1</td>
<td>$15.6</td>
<td>$16.1</td>
<td>$280.00</td>
<td>$103.0K</td>
<td>1.1K</td>
<td style="text-align: right;">396</td>
</tr>
</tbody>
</table>

<h3>About Danaher</h3>
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divesititure of its environmental and applied solutions group, Veralto.
Having examined the options trading patterns of Danaher, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Danaher</h3>
<ul>
<li>With a volume of 1,530,674, the price of DHR is down -2.38% at $265.61. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 0 days.</li>
</ul>
<h3>Professional Analyst Ratings for Danaher</h3>
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $296.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Evercore ISI Group continues to hold a Outperform rating for Danaher, targeting a price of $278. 
&#x2A; In a cautious move, an analyst from Stephens &amp; Co. downgraded its rating to Overweight, setting a price target of $315. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Danaher options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

A Closer Look at Danaher's Options Market Dynamics

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Wingstop upgraded, Estee Lauder downgraded: Wall Street's top analyst calls

Wells Fargo's Growth List – META, CPAY, DXCM, and more

Wells Fargo's 'Focus List' – GOOGL, TJX, XOM, JPM

Weitz Conservative Allocation Fund Q3 2024 Commentary

Thermo Fisher Scientific: Near The Bottom And Attractively Valued

Revving Up: 2 Underperforming Dividend Giants Ready To Outshine

Third Point LLC disclosed in an SEC filing its holdings as of September 30, 2024. Third Point's new buys during the third quarter included, by size...

Third Point exits Alphabet, cuts stakes in Microsoft, Amazon, Meta, Apple

DiamondRock Hospitality acquires the AC Hotel Minneapolis Downtown

Bearish flow noted in Danaher (DHR) with 1,213 puts trading, or 1.4x expected. Most active are Dec-24 250 calls and Dec-24 230 puts, with total vol...

Danaher put volume heavy and directionally bearish

Least shorted S&P 500 stocks in October

ABNB

AVGO

BBWI

BRZE

BURL

CPAY

CRWD

CTAS

DXCM

ENLC

FERG

FLUT

GOOG

GOOGL

ILMN

INTU

KEYS

MCHP

NFLX

NVDA

ODFL

ORCL

ORIC

ORLY

PAYC

PLNT

REIT

SBAC

SMCI

SPGI

TECH

TERN

TMUS

TREX

TSLA

UBER

VNDA

WDAY

WING

Press Releases

Danaher Launches Beacon Research Collaboration with Stanford University Aiming to Build Next Generation of Smart Microscopes for Cancer Drug Screening

Danaher Releases 2024 Sustainability Report

Danaher Announces Two New Centers of Innovation in Diagnostics to Transform Precision Medicine Development

Beckman Coulter's DxI 9000 Immunoassay Analyzer Honored at Premier, Inc.'s Annual Supplier Innovation Celebration

Danaher to Webcast Diagnostics Investor & Analyst Meeting in Washington, D.C.

Danaher Confirms Third Quarter and Full Year 2024 Guidance

Dividends

Danaher Announces Quarterly Dividend

Beckman Coulter and Scopio Labs Add World's First Digital Bone Marrow Imaging and Analysis to Long-Term Partnership

Danaher Schedules Third Quarter 2024 Earnings Conference Call

Danaher Reports Third Quarter 2024 Results

Agilent Technologies

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Cytek Biosciences

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Danaher

매도 수량

Danaher (NYSE:DHR) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌